ArticleFrontiers in medicine2026
Impact of pathologically diagnosed metabolic dysfunction-associated steatohepatitis on weight loss outcomes following sleeve gastrectomy.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The impact of metabolic dysfunction-associated steatohepatitis (MASH) on post-operative weight loss outcomes remains unclear. This study aims to investigate the effects of preoperative concomitant MASH on weight loss outcomes and metabolic improvements following laparoscopic sleeve gastrectomy (LSG). Methods: A retrospective analysis was performed on the clinical data of 226 patients with obesity who underwent LSG and concurrent intraoperative liver biopsy. Univariate analysis, multivariate analysis, and general linear models were employed to evaluate differences in the dynamic trajectories of post-operative weight loss between the groups. Additionally, Kaplan-Meier survival analysis was utilized to compare the time required to achieve successful weight loss outcomes. Results: Preoperative body mass index (BMI) and the presence of MASH were independent negative predictors of percentage excess weight loss (%EWL) and percentage total weight loss (%TWL) ( Conclusion: Preoperative MASH is significantly associated with lower post-operative weight loss. Compared to non-MASH patients, patients with MASH experienced a delay in achieving satisfactory weight loss outcomes within the first year after surgery, and this was significantly associated with a lower post-operative %EWL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.